drugset / Trial / NCT00538590

Ologen Collagen Matrix Safety and Effective Comparison With Mitomycin-C(MMC) in Glaucoma Surgery

NCT00538590

Phase 4 Completed 20 enrolled Pro Top & Mediking Company Limited
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the safety and effectiveness of oculusgen (ologen) collagen matrix implantation and Mitomycin-C(MMC) in glaucoma surgery.

Timeline

Start
2007-07
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mitomycin C Other / unclassified 0.2 mg/ml Other
Comparator Mitomycin C Other / unclassified 0.4 mg/ml Other

Indications